This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
UnitedHealth (UNH) Scales a 52-Week High on Recent Deals
by Zacks Equity Research
UnitedHealth's (UNH) shares are riding on its recent acquisition announcements.
UnitedHealth to Buy Advisory Board's Health Care Business
by Zacks Equity Research
The acquisition of Advisory Board's health care business will bolster UnitedHealth's (UNH) health management business.
Humana (HUM) Hits 52-Week High on Solid Q2, Raised Outlook
by Zacks Equity Research
Humana's (HUM) shares have been favored by its strong earnings performance, guidance raise and completion of accelerated share buyback.
Advisory Board (ABCO) in Focus: Stock Moves 6.4% Higher
by Zacks Equity Research
Advisory Board (ABCO) shares rose more than 6% in the last trading session, amid huge volumes.
Advisory Board (ABCO) in Focus: Stock Moves 5.4% Higher
by Zacks Equity Research
Advisory Board (ABCO) was a big mover last session, as the company saw its shares rise over 5% on the day.
Allergan's Restasis Now Available in Multidose Bottle in U.S.
by Zacks Equity Research
Allergan plc (AGN) recently announced that its marketed drug Restasis (cyclosporine ophthalmic emulsion) 0.05% is now available in multidose bottles in the U.S.
Ultragenyx's Seizure Candidate UX007 Fails in Phase II Study
by Zacks Equity Research
Ultragenyx Pharmaceutical Inc. (RARE) recently announced that its pipeline candidate UX007 (triheptanoin) failed to meet the primary endpoint in a phase II study evaluating it for the treatment of patients with Glut1 DS with seizures.
Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down
by Zacks Equity Research
Shares of Array BioPharma Inc. (ARRY) slipped 2.30% after the company announced that it has withdrawn its new drug application (NDA) for its pipeline candidate, binimetinib, from the FDA's Division of Oncology Products 2.
Jazz Sleep Disorder Drug Positive in Phase III Studies
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced positive efficacy results from two phase III studies evaluating the safety and efficacy of its lead pipeline candidate JZP-110 for the treatment of excessive sleepiness.
BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet
by Zacks Equity Research
BioDelivery Sciences International, Inc. (BDSI) reported loss of 29 cents per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of 28 cents.
Teva Launches Authorized Generic of Allergan's Minastrin
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) recently launched an authorized generic version of Allergan plc???s (AGN) oral contraceptive, Minastrin 24 Fe1, in the U.S.
Jazz Initiates Phase III Study for Narcolepsy Candidate
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) recently announced the initiation of patient enrollment in a phase III study evaluating the efficacy and safety of its pipeline candidate, JZP-258, for the potential treatment of adult narcolepsy patients.
AstraZeneca's Cancer Drug Lynparza Positive in Phase III
by Zacks Equity Research
AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.
Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents.
Community Health Continues Divestiture, to Sell 4 Hospitals
by Zacks Equity Research
In its bid to divest units to lower its debt level, Community Health Systems, Inc. (CYH) has struck an agreement with PinnacleHealth System to sell four Pennsylvania hospitals and their associated assets.
Teladoc Continues to Grow in Booming Telehealth Industry
by Zacks Equity Research
Teladoc Inc. (TDOC), a premier telehealth services provider, is rapidly expanding its business in the booming telehealth services industry.
Advisory Board Company (ABCO) Enters Overbought Territory
by Zacks Equity Research
The Advisory Board Company (ABCO) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
The Advisory Board (ABCO) in Focus: Stock Surges 16.2%
by Zacks Equity Research
The Advisory Board Company (ABCO) was a big mover last session, as the company saw its shares surged over 16% on the day.